← Back to Directory

X4 Pharmaceuticals, Inc. (XFOR) - Latest Market Data

Track the most recent price, market cap, volume, and performance data for X4 Pharmaceuticals, Inc. (XFOR).

Download PennyGems on Google Play Download PennyGems on the App Store

Equity Details

Price & Market Data

Price: $4.40

Daily Change: -$0.10 / 2.27%

Daily Range: $4.20 - $4.62

Market Cap: $409,347,473

Daily Volume: 401,007

Performance Metrics

1 Week: 3.33%

1 Month: 5.08%

3 Months: 16.98%

6 Months: 16.98%

1 Year: 29.94%

YTD: 8.50%

About X4 Pharmaceuticals, Inc. (XFOR)

Explore comprehensive market data for X4 Pharmaceuticals, Inc. (XFOR). Currently priced at 4.40, observe its daily movement of -$0.10 / 2.27%. The total market value is 409,347,473. Review its performance across various timeframes, including the last week, month, and year, to understand its trajectory.

Company Details

Employees: 45

Sector: Health technology

Industry: Biotechnology

Country: United States

Details

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.

Selected stocks

Rezolute, Inc. (RZLT)

Senstar Technologies Corporation (SNT)

Tokyo Lifestyle Co., Ltd. (TKLF)

Integra Resources Corp. (ITRG)

Calidi Biotherapeutics, Inc. (CLDI)